Dan is a European and Chartered UK Patent Attorney. He joined Dehns in 2001 after completing a BSc and then a PhD, both from the University of Bristol. He became an Associate of the firm in 2008 and Senior Associate in 2018.
Dan’s clients range from small biotech start-ups and university spin-outs/technology transfer offices to multinational biotech/pharma corporations, with particular experience assisting UK, US and Scandinavian start-ups protect and exploit their IP and assess their freedom to operate in their chosen fields.
His work includes the drafting and prosecution of patent applications and the opposition of patents (offensive and defensive), including appeal work. Dan provides straightforward, business-oriented advice to clients on all aspects of patent law in this technical area, including patentability, infringement and validity analyses and commercially-focused assistance with the cost-effective development and management of global patent portfolios.
His subject matter expertise covers the full spectrum of industrial and medical biotechnology. Within the health sector, he has a particular focus on molecular medicine; molecular diagnostics, biomarkers and personalised medicine; pharmaceuticals (human and veterinary); medical devices; advanced drug delivery; and wound healing products. His industrial practice has a particular focus on protein purification from blood products and advanced cell-factories for the industrial production of proteins. Dan also handles cases directed to microbiological and non-microbiological processes for the production of poly/oligosaccharides and engineered enzymes for removing contaminating nucleic acids from solutions.
BSc (Hons) (First Class), Biochemistry, University of Bristol, 1998
PhD “The intracellular mechanisms of thapsigargin-induced inhibition of human vascular smooth muscle cell proliferation”, University of Bristol, 2001
Dan was recognised as a “rising star” in the 2018 edition of Managing Intellectual Property’s IP Stars publication.
Dan frequently writes on the IP industry and the Life Sciences sector; see below for his articles.